Trinity Biotech (TRIB) Cash & Current Investments (2009 - 2025)

Trinity Biotech has reported Cash & Current Investments for 17 years, with the latest figure at $5.1 million in Q4 2025.

• Quarterly Cash & Current Investments fell 32.59% year-over-year to $5.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.1 million (down 32.59% YoY) and the FY2025 annual result came in at $5.1 million, down 32.59% from the prior year.
• Cash & Current Investments slipped to $5.1 million in Q4 2025 per TRIB's latest filing, from $7.9 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $32.3 million in Q1 2021 and troughed at $2.8 million in Q3 2024.
• A 5-year average of $14.1 million and a median of $9.0 million in 2022 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2021 and 2024: Cash & Current Investments surged 143.71% in 2021, then plunged 80.04% in 2024.
• Over 5 years, Cash & Current Investments stood at $25.9 million in 2021, then plunged by 74.23% to $6.7 million in 2022, then plunged by 41.73% to $3.9 million in 2023, then soared by 95.89% to $7.6 million in 2024, then tumbled by 32.59% to $5.1 million in 2025.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $5.1 million, $7.9 million, and $7.6 million for Q4 2025, Q2 2025, and Q4 2024 respectively.